Lifeist's Mikra Receives First Purchase Order From Leading Global Health And Wellness Brand“GNC”

(MENAFN- GlobeNewsWire - Nasdaq)

TORONTO, May 09, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the“Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF ), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has received its first purchase order from GNC Holdings, LLC (“GNC”) for Mikra's CELLFTM v1.2. GNC is a leading global health and wellness brand that provides high-quality, science-based products and solutions to consumers.

“Launching our newly formulated cellular health nutraceutical gel CELLFTM v1.2 with GNC, the global premier health and wellness brand, is a significant milestone for Mikra and Lifeist,” said Faraaz Jamal, CEO of Mikra.“We have been working closely with the team at GNC to make the U.S. roll out of CELLFTM v1.2 a success. They have been extremely helpful fine tuning our marketing strategies, packaging, and display designs, to create the greatest impact within their online and retail GNC stores. We look forward to expanding this strategic relationship beyond CELLFTM v1.2 to include additional product lines as they become available.”

“Congrats to Faraaz and his team who have been working tirelessly to make the GNC distribution of CELLFTM v1.2 a reality,” said Meni Morim, CEO of Lifeist.“For the launch we will take a phased approach, targeting a specific number of GNC stores before expanding to more stores to ensure that we're scaling effectively and meeting consumer needs. I would like to also announce that as Mikra enters this new stage of growth, Faraaz Jamal, is transitioning from his role as COO of Lifeist to focus solely on Mikra to enable growth and lead Mikra into the future.”

On January 12, 2023 the Company announced a distribution agreement with GNC to make it the exclusive distribution partner for CELLFTM v1.2 and its future derivatives in the United States through retail stores, at and on GNC's channel on GNC is a leading global health and wellness brand that provides high-quality, science-based products and solutions consumers need to live mighty, live fit, and live well. With over 4,000 retail locations across the United States and over 2,000 internationally, GNC is the largest global specialty retailer of nutritional products.

CELLFTM v1.2 is a cellular health nutraceutical gel, engineered with a natural biological delivery system to pass through gastric environments unchanged and deliver directly to cells. It is formulated with bioactive compounds clinically studied in more than 145 human studies to positively impact brain, heart, skin and muscular systems.

CELLFTM v1.2 is currently available on Mikra's proprietary e-commerce platform and, CELLFTM v1.2 will also be available on, GNC's Amazon store and in select stores nationwide beginning June 2023.

Mikra is pushing biosciences beyond the expected with the belief it's possible to add more valuable, enjoyable years to your life through rebuilding and protecting your cellular health.

Rebuild and protect your overall health with Mikra.

About GNC

GNC is a leading global health and wellness brand that provides high-quality, science-based products and solutions consumers need to live mighty, live fit, and Live Well. The brand touches consumers worldwide by providing its products and services through company-owned retail locations, domestic and international franchise locations, digital commerce and strong wholesale and retail partnerships across the globe. GNC's diversified, multi-channel business model has worldwide reach and a well-recognized, trusted brand. By combining exceptional innovation, product development capabilities and an extensive global distribution network, GNC manages a best-in-class product portfolio. .

About Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia's largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health.

Information on Lifeist and its businesses can be accessed through the links below:


Meni Morim, CEO
Lifeist Wellness Inc.
Ph: 647-362-0390

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information

This news release contains“forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as“may”,“expect”,“likely”,“should”,“would”,“plan”,“anticipate”,“intend”,“potential”,“proposed”,“estimate”,“believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions“may” or“will” happen.

The forward-looking information contained herein, including, without limitation, statements related to the expected availability for purchase by consumers of CELLFTM v1.2 on, GNC's Amazon store and in select GNC stores nationwide beginning June 2023, anticipated future distribution in additional GNC stores and the expected expansion of the strategic relationship with GNC beyond CELLFTM v1.2 to include additional product lines, are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, expectations that CELLFTM v1.2 will be available for purchase through GNC as anticipated and in a timely manner and gain market acceptance, Mikra will be able to develop new product lines as anticipated, sales level of CELLFTM v1.2 will be as anticipated and economically viable for Mikra and the Company, its expectation that the market for nutraceutical products in general will remain strong and will continue to grow as currently anticipated, the market for nutraceutical products will continue to be a multi-billion dollar market, the introduction of new products, brands and distribution channels will generate additional awareness of Mikra's existing and future products and increase revenue. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: unforeseen developments that would delay Mikra's ability to begin sales of CELLFTM v1.2 via GNC as anticipated, sales of CELLFTM v1.2 failing to achieve the sales level and other benefits expected from being available for purchase at GNC stores and online, the exclusive distribution relationship between the Company and GNC failing to demonstrate and achieve its anticipated benefits, the Company's inability to continue to develop Mikra's business as a whole, including its inability to develop new products or increase distribution through retail and online channels, unanticipated changes to current regulations that would adversely impact Mikra's business, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular, including CELLFTM v1.2, does not develop as anticipated and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A which has been filed under the Company's SEDAR profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Lifeist Wellness Inc.

Tags wellness health nutraceutical


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.